News Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			5-day change	1st Jan Change
66.28 ^USD	+1.42%		+2.63%	+51.22%

10-09	Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says	MT
10-09	RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating	MT

All News

Mentions Relevance

10-15	Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026	BU
10-09	Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says	MT
10-09	RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating	MT
10-08	RBC Trims Price Target on Exelixis to $45 From $46, Keeps Sector Perform Rating	MT
09-15	Exelixis, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM
09-11	Exelixis, Inc. Extends FDA Review Period for Zanzalintinib New Drug Application in Combination with Atezolizumab for Metastatic Colorectal Cancer	CI
09-11	FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer	DJ
09-11	Exelixis Says FDA Extended Review Period for Colorectal Cancer Drug	MT
09-11	US FDA extends review of Exelixis' cancer drug	RE
09-09	Exelixis, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08:40 AM
09-08	Exelixis, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-08-2026 11:00 AM
09-01	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September	BU
08-31	Exelixis Wins Appeal in Patent Case Against MSN Laboratories	MT
08-31	Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories	BU
08-05	Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026
08-05	(EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B	MT
08-05	Earnings Flash (EXEL) Exelixis, Inc. Reports Q2 Revenue $628.7M, vs. FactSet Est of $636.4M	MT
08-05	Earnings Flash (EXEL) Exelixis Posts Q2 Revenue $628.7M, vs. FactSet Est of $636.4M	MT
08-05	Exelixis Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours	MT
08-05	Exelixis: Q2 Earnings Snapshot	AQ
08-05	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on May 5, 2026.	CI
08-05	Tranche Update on Exelixis, Inc.'s Equity Buyback Plan announced on November 4, 2025.	CI
08-05	Exelixis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-05	Earnings Flash (EXEL) Exelixis, Inc. Posts Q2 Adjusted EPS $0.91 per Share, vs. FactSet Est of $0.85	MT
08-05	Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update	BU